SCHEMBL4129083

SCHEMBL4129083

CC(C)(C)OC(=O)NCCCOc1cccc(-c2ncnc3c2ncn3C2CCCCO2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 3/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP2C19 P33261 1/20 0.41
DOT1L Q8TEK3 1/20 0.40
CYP1A2 P05177 2/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.37
CYP2C9 P11712 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
APEX1 P27695 1/20 0.37
PI4KA P42356 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13651692 0.84 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL29925873 0.76 ATR (0.43) ATR
SCHEMBL27032273 0.76 ATR (0.43) ATR
SCHEMBL5732295 0.76 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL5732302 0.76 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL5732299 0.76 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL27032041 0.75 ATR (0.45) ATR
SCHEMBL29925841 0.75 ATR (0.45) ATR
SCHEMBL14249959 0.74 ATR (0.41) ATRCYP1A2TSHRHSD17B10ALDH1A1
SCHEMBL14296954 0.74 FLT3 (0.41) ATRCYP1A2TSHRHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
WO-2007125315-A2 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253718-A1 Pharmaceutical Compounds GRK3, CNKSR1, CSNK1G3 ATR 2420/4885NPC1 1129/4885RAB9A 1693/4885
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors OXSR1, CDK1, CDK3 ATR 714/4885NPC1 3269/4885RAB9A 3680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.